Literature DB >> 12023376

IL-18 contributes to host resistance against infection with Pseudomonas aeruginosa through induction of IFN-gamma production.

Xi Huang1, Sharon A McClellan, Ronald P Barrett, Linda D Hazlett.   

Abstract

Pseudomonas aeruginosa keratitis destroys the cornea in susceptible (B6), but not resistant (BALB/c) mice. To determine mechanisms mediating resistance, the role of IFN-gamma, IL-12, and IL-18 was tested in BALB/c mice. RT-PCR analysis detected IFN-gamma mRNA expression levels in cornea that were significantly increased at 1-7 days postinfection. IL-18 mRNA was detected constitutively in cornea and, at 1-7 days postinfection, levels were elevated significantly, while no IL-12 mRNA was similarly detected. To test whether IL-18 contributed to IFN-gamma production, mice were treated with anti-IL-18 mAb. Treatment decreased corneal IFN-gamma mRNA levels, and bacterial load and disease increased/worsened, compared with IgG-treated mice. To stringently examine the role of IFN-gamma in bacterial killing, knockout (-/-) vs wild-type (wt) mice also were tested. All corneas perforated, and bacterial load was increased significantly in -/- vs wt mice. Because disease severity was increased in IFN-gamma(-/-) vs IL-18-neutralized mice, and since IL-18 also induces production of TNF, we tested for TNF-alpha in both groups. ELISA analysis demonstrated significantly elevated corneal TNF-alpha protein levels in IFN-gamma(-/-) vs wt mice after infection. In contrast, RT-PCR analysis of IL-18-neutralized vs IgG-treated infected mice revealed decreased corneal TNF-alpha mRNA expression. Next, to resolve whether TNF was required for bacterial killing, TNF-alpha was neutralized in BALB/c mice. No difference in corneal bacterial load was detected in neutralized vs IgG-treated mice. These data provide evidence that IL-18 contributes to the resistance response by induction of IFN-gamma and that IFN-gamma is required for bacterial killing.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12023376     DOI: 10.4049/jimmunol.168.11.5756

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  7 in total

1.  Treatment with interleukin-18 binding protein ameliorates Toxoplasma gondii-induced small intestinal pathology that is induced by bone marrow cell-derived interleukin-18.

Authors:  D Struck; I Frank; S Enders; U Steinhoff; C Schmidt; A Stallmach; O Liesenfeld; M M Heimesaat
Journal:  Eur J Microbiol Immunol (Bp)       Date:  2012-09-10

2.  Cornea: Window to Ocular Immunology.

Authors:  Jerry Y Niederkorn
Journal:  Curr Immunol Rev       Date:  2011-08

Review 3.  Interleukin-18 as a therapeutic target in acute myocardial infarction and heart failure.

Authors:  Laura C O'Brien; Eleonora Mezzaroma; Benjamin W Van Tassell; Carlo Marchetti; Salvatore Carbone; Antonio Abbate; Stefano Toldo
Journal:  Mol Med       Date:  2014-06-12       Impact factor: 6.354

4.  Limited role for interleukin-18 in the host protection response to pulmonary infection with Pseudomonas aeruginosa in mice.

Authors:  Chikara Nakasone; Kazuyoshi Kawakami; Tomoaki Hoshino; Yusuke Kawase; Koichi Yokota; Kohichiro Yoshino; Kiyoshi Takeda; Shizuo Akira; Atsushi Saito
Journal:  Infect Immun       Date:  2004-10       Impact factor: 3.441

5.  IL-33 shifts macrophage polarization, promoting resistance against Pseudomonas aeruginosa keratitis.

Authors:  Linda D Hazlett; Sharon A McClellan; Ronald P Barrett; Xi Huang; Yunfan Zhang; Minhao Wu; Nico van Rooijen; Elizabeth Szliter
Journal:  Invest Ophthalmol Vis Sci       Date:  2009-11-05       Impact factor: 4.799

Review 6.  Foundational concepts in the biology of bacterial keratitis.

Authors:  Lawson Ung; James Chodosh
Journal:  Exp Eye Res       Date:  2021-06-05       Impact factor: 3.770

7.  NLRC4 regulates caspase-1 and IL-1beta production in a CD11blowLy6Glow population of cells required for resistance to Pseudomonas aeruginosa keratitis.

Authors:  Sharon A McClellan; Andrew Jerome; Susmit Suvas; Linda D Hazlett
Journal:  PLoS One       Date:  2017-09-29       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.